Publications by authors named "Amalie Q Rousing"
Key Points: This study developed a urine acid/base score to assess tubular acid excretion capacity and identify early acid retention in CKD. The results show that early signs of acid retention (a low acid/base score) are associated with a higher risk for CKD progression. Future research should address if a low urine acid/base score can be improved and if this translates into clinically meaningful effects.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how renal excretion of bicarbonate (HCO₃) works in people with cystic fibrosis (pwCF), suggesting that urine HCO₃ after oral loading could serve as a simple CFTR function biomarker.
- Researchers measured various urine acid/base parameters in control individuals and pwCF to analyze the physiological response to HCO₃ loading and its association with CF disease characteristics.
- Results indicated that urine acid/base excretion changes correlate with CF disease severity and treatment effects, supporting the idea that measuring urine HCO₃ can effectively reflect CFTR function and provide insights into CFTR modulation therapies.
Background & Aims: Acid-base disturbances are common in short bowel (SB) patients due to increased intestinal bicarbonate loss. However, the resulting systemic acid load has not been quantified. Base excess is used to monitor metabolic acid-base disturbances but inadequately reflects the acid load.
View Article and Find Full Text PDFTrimethoprim inhibits renal H-K-ATPase in states of K depletion.
Am J Physiol Renal Physiol
January 2024
There is growing consensus that under physiological conditions, collecting duct H secretion is independent of epithelial Na channel (ENaC) activity. We have recently shown that the direct ENaC inhibitor benzamil acutely impairs H excretion by blocking renal H-K-ATPase. However, the question remains whether inhibition of ENaC per se causes alterations in renal H excretion.
View Article and Find Full Text PDFBackground: In cystic fibrosis (CF), renal base excretion is impaired. Accordingly, challenged urine bicarbonate excretion may be an in vivo biomarker of cystic fibrosis transmembrane conductance regulator (CFTR) function.
Objective: To evaluate the association between challenged bicarbonate excretion and clinical characteristics at baseline, quantify the CFTR modulator drug elexacaftor/tezacaftor/ivacaftor-induced changes of challenged bicarbonate excretion after 6 months of treatment, and characterize the intraindividual variation in healthy adults.